ES2281934T3 - Procedimiento para la deteccion de anticuerpos en una muestra. - Google Patents
Procedimiento para la deteccion de anticuerpos en una muestra. Download PDFInfo
- Publication number
- ES2281934T3 ES2281934T3 ES98948398T ES98948398T ES2281934T3 ES 2281934 T3 ES2281934 T3 ES 2281934T3 ES 98948398 T ES98948398 T ES 98948398T ES 98948398 T ES98948398 T ES 98948398T ES 2281934 T3 ES2281934 T3 ES 2281934T3
- Authority
- ES
- Spain
- Prior art keywords
- ligand
- coupled
- subject
- antibodies
- target antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 43
- 238000001514 detection method Methods 0.000 title claims abstract description 29
- 239000000427 antigen Substances 0.000 claims abstract description 79
- 108091007433 antigens Proteins 0.000 claims abstract description 79
- 102000036639 antigens Human genes 0.000 claims abstract description 79
- 238000012360 testing method Methods 0.000 claims abstract description 58
- 239000003446 ligand Substances 0.000 claims abstract description 43
- 239000003550 marker Substances 0.000 claims abstract description 28
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 23
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 23
- 239000007790 solid phase Substances 0.000 claims abstract description 21
- 238000011002 quantification Methods 0.000 claims abstract description 10
- 238000006243 chemical reaction Methods 0.000 claims abstract description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 39
- 238000003556 assay Methods 0.000 claims description 15
- 241000700605 Viruses Species 0.000 claims description 10
- 238000011534 incubation Methods 0.000 claims description 9
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 6
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 6
- 239000012071 phase Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 241000711549 Hepacivirus C Species 0.000 claims description 4
- 208000005176 Hepatitis C Diseases 0.000 claims description 4
- -1 acrylic ester Chemical class 0.000 claims description 3
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical group C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 claims description 3
- 108090000848 Ubiquitin Proteins 0.000 claims description 2
- 102000044159 Ubiquitin Human genes 0.000 claims description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical compound C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 claims description 2
- 150000002148 esters Chemical group 0.000 claims 1
- 230000004927 fusion Effects 0.000 abstract description 5
- 108090000623 proteins and genes Proteins 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 23
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000002245 particle Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 4
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 4
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 4
- 229960003942 amphotericin b Drugs 0.000 description 4
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 239000012445 acidic reagent Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 238000002764 solid phase assay Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000006226 wash reagent Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical compound SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/82—Hepatitis associated antigens and antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5970397P | 1997-09-22 | 1997-09-22 | |
| US59703P | 1997-09-22 | ||
| US8392198P | 1998-05-01 | 1998-05-01 | |
| US83921P | 1998-05-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2281934T3 true ES2281934T3 (es) | 2007-10-01 |
Family
ID=26739077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98948398T Expired - Lifetime ES2281934T3 (es) | 1997-09-22 | 1998-09-22 | Procedimiento para la deteccion de anticuerpos en una muestra. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6391540B1 (enExample) |
| EP (1) | EP1021719B1 (enExample) |
| JP (1) | JP4124961B2 (enExample) |
| AT (1) | ATE354800T1 (enExample) |
| AU (1) | AU9497998A (enExample) |
| CA (1) | CA2303123C (enExample) |
| CY (1) | CY1107621T1 (enExample) |
| DE (1) | DE69837155T2 (enExample) |
| DK (1) | DK1021719T3 (enExample) |
| ES (1) | ES2281934T3 (enExample) |
| PT (1) | PT1021719E (enExample) |
| WO (1) | WO1999015898A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1295126B1 (en) * | 1999-07-28 | 2007-01-24 | Novartis Vaccines and Diagnostics, Inc. | Hepatitis c viral antigen immunoassay detection systems |
| US6815160B1 (en) | 1999-07-28 | 2004-11-09 | Chiron Corporation | Hepatitis C viral antigen immunoassay detection systems |
| US6995299B2 (en) * | 1999-11-02 | 2006-02-07 | University Of Connecticut | Propagation of human hepatocytes in non-human animals |
| DE10006432A1 (de) * | 2000-02-14 | 2001-08-16 | Ganzimmun Inst Fuer Ganzheitli | Verfahren zum Nachweis von Helicobacter pylori in Stuhl- und Speichelproben |
| BRPI0111731C1 (pt) * | 2000-06-15 | 2021-07-27 | Chiron Corp | suporte sólido de imunoensaio, métodos de detecção de infecção pelo vírus da hepatite c (hcv) em uma amostra biológica, e de produção de um suporte sólido de imunoensaio, e, kit de teste de imunodiagnóstico |
| GB0325483D0 (en) * | 2003-10-31 | 2003-12-03 | Plasmacute As | Assay |
| JP2007532905A (ja) * | 2004-04-15 | 2007-11-15 | アライド・バイオテック・インコーポレーテッド | ウイルス感染の検出のための方法と装置 |
| JP5414667B2 (ja) | 2007-05-08 | 2014-02-12 | エフ．ホフマン−ラ ロシュ アーゲー | 特異的免疫グロブリンクラスｇ抗体の検出方法 |
| CN105486856A (zh) * | 2015-12-24 | 2016-04-13 | 泰州泽成生物技术有限公司 | 一种定性检测丙型肝炎抗体的试剂盒及其制备方法和应用 |
| CN107167584B (zh) * | 2017-05-27 | 2020-03-03 | 北京热景生物技术股份有限公司 | 化学发光免疫分析仪 |
| JP7198932B2 (ja) | 2018-09-18 | 2023-01-04 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド | ジカウイルスイムノアッセイの方法および試薬 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2556840B1 (fr) | 1983-12-16 | 1987-12-24 | Immunotech Sa | Procede de dosage in vitro des immunoglobulines specifiques d'un ou plusieurs allergenes et reactifs et moyens pour la mise en oeuvre de ce procede |
| US4737453A (en) * | 1984-12-12 | 1988-04-12 | Immunomedics, Inc. | Sandwich immunoassay utilizing a separation specific binding substance |
| EP0341439B1 (en) | 1988-05-11 | 1993-08-04 | Abbott Laboratories | Method for increasing specificity in competitive immunoassays |
| US5656426A (en) | 1988-08-01 | 1997-08-12 | Chiron Diagnostics Corporation | Functionaized hydrophilic acridinium esters |
| KR100206150B1 (ko) * | 1990-04-04 | 1999-07-01 | 로버트 피. 블랙버언 | 항-에이치씨브이 항체에 대한 면역분석용 씨형 간염 바이러스(에이치디브이)항원의 조합체 |
| EP0473065A3 (en) * | 1990-08-29 | 1992-08-26 | Abbott Laboratories | Simultaneous assay for detecting two or more analytes |
| CA2095825A1 (en) | 1990-11-09 | 1992-05-10 | Roger C. Hu | Amplified heterogeneous chemiluminescent immunoassay |
| JPH04310861A (ja) * | 1991-04-09 | 1992-11-02 | Kazuo Yanagi | 抗ｅｂｎａ抗体の測定方法および抗ｅｂｎａ抗体測定キット |
| CA2104596A1 (en) * | 1992-01-06 | 1993-07-07 | Dade International Inc. | Multi-test immunochemical reagent and method to use same |
| JPH06213895A (ja) * | 1992-10-16 | 1994-08-05 | Evernew Biotec Inc | Ｃ型肝炎の急性期の決定方法 |
| US5395752A (en) | 1993-03-19 | 1995-03-07 | Ciba Corning Diagnostics Corp. | Long emission wavelength chemiluminescent compounds and their use in test assays |
| SK153594A3 (en) * | 1993-04-14 | 1995-07-11 | Int Murex Tech Corp | Determination method of antibodies to two or bigger number of different patogens in tested sample |
| KR100312534B1 (ko) | 1993-04-28 | 2002-05-13 | 성재갑 | 씨(c)형간염및비(b)형간염동시측정면역블롯검정키트및면역블롯검정법 |
| JP3751315B2 (ja) * | 1993-05-05 | 2006-03-01 | コモン サーヴィシス エージェンシー | Ｃ型肝炎ウイルス４、５及び６型 |
| WO1994026932A1 (en) | 1993-05-13 | 1994-11-24 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nucleic acid tagged immunoassay |
| DE19502386A1 (de) | 1995-01-26 | 1996-08-01 | Boehringer Mannheim Gmbh | Stabilisierung von Peptiden und Polypeptiden in immunologischen Tests durch Zusatz von kleinen Hitzeschockproteinen |
| US5705330A (en) | 1995-04-14 | 1998-01-06 | Abbott Laboratories | Chemiluminescent immunoassay for antibody detection |
| US5616460A (en) | 1995-06-07 | 1997-04-01 | Abbott Laboratories | Buffer composition for reagents for immunoassay |
| DK0935662T3 (da) | 1996-05-24 | 2006-03-06 | Chiron Corp | Fusionsprotein med multiple epitoper |
-
1998
- 1998-09-22 CA CA002303123A patent/CA2303123C/en not_active Expired - Lifetime
- 1998-09-22 DE DE69837155T patent/DE69837155T2/de not_active Expired - Lifetime
- 1998-09-22 AU AU94979/98A patent/AU9497998A/en not_active Abandoned
- 1998-09-22 EP EP98948398A patent/EP1021719B1/en not_active Expired - Lifetime
- 1998-09-22 AT AT98948398T patent/ATE354800T1/de active
- 1998-09-22 US US09/158,301 patent/US6391540B1/en not_active Expired - Lifetime
- 1998-09-22 PT PT98948398T patent/PT1021719E/pt unknown
- 1998-09-22 JP JP2000513145A patent/JP4124961B2/ja not_active Expired - Lifetime
- 1998-09-22 WO PCT/US1998/019693 patent/WO1999015898A1/en not_active Ceased
- 1998-09-22 ES ES98948398T patent/ES2281934T3/es not_active Expired - Lifetime
- 1998-09-22 DK DK98948398T patent/DK1021719T3/da active
-
2007
- 2007-04-26 CY CY20071100557T patent/CY1107621T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69837155T2 (de) | 2007-06-21 |
| CA2303123A1 (en) | 1999-04-01 |
| US6391540B1 (en) | 2002-05-21 |
| DE69837155D1 (de) | 2007-04-05 |
| JP4124961B2 (ja) | 2008-07-23 |
| DK1021719T3 (da) | 2007-06-18 |
| EP1021719A1 (en) | 2000-07-26 |
| CY1107621T1 (el) | 2013-03-13 |
| ATE354800T1 (de) | 2007-03-15 |
| CA2303123C (en) | 2006-04-11 |
| WO1999015898A1 (en) | 1999-04-01 |
| PT1021719E (pt) | 2007-03-30 |
| AU9497998A (en) | 1999-04-12 |
| JP2001517797A (ja) | 2001-10-09 |
| EP1021719B1 (en) | 2007-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6537745B2 (en) | Buffers for stabilizing antigens | |
| ES2251028T3 (es) | Proteina de fusion de epitopos multiples. | |
| US6514731B1 (en) | Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens | |
| US6596476B1 (en) | Hepatitis C assay | |
| ES2275528T3 (es) | Metodos para detectar simultaneamente ambos miembros de un par de union. | |
| CN105228649A (zh) | Hcv抗原-抗体组合测定和方法以及用在其中的组合物 | |
| EP1328811B1 (en) | Hcv mosaic antigen composition | |
| EP0642666B1 (en) | Hepatitis c assay | |
| US6391540B1 (en) | Method for detecting antibodies in a sample | |
| KR100500793B1 (ko) | C형간염바이러스감염증진단약 | |
| BRPI0200986B1 (pt) | Método de determinação da presença de hcv em uma amostra | |
| JP4975601B2 (ja) | Ｈｃｖ抗体測定用試薬キット及びｈｃｖ抗体測定方法 | |
| EP1978365B1 (en) | Reagent kit and method for measuring HCV antibody | |
| EP1590671A1 (en) | Improved method of detection of hcv antibodies in combination assay or sole antibody assay | |
| US20030170618A1 (en) | Buffers for stabilizing antigens | |
| TW201337268A (zh) | 一種偵測ｃ型肝炎病毒感染之方法 | |
| JP4975600B2 (ja) | Ｈｃｖ抗体測定用試薬キット及びｈｃｖ抗体測定方法 |